176 related articles for article (PubMed ID: 25878009)
1. High-dose intravenous interferon-beta in multiple sclerosis patients with high-titer neutralizing antibodies (HINABS II) - A pilot study.
Hegen H; Guger M; Harrer A; Hoelzl M; Kraus J; Skrobal A; Schautzer F; Schmidegg S; Schocke M; Deisenhammer F
Mult Scler Relat Disord; 2014 Mar; 3(2):220-6. PubMed ID: 25878009
[TBL] [Abstract][Full Text] [Related]
2. High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study.
Millonig A; Rudzki D; Hölzl M; Ehling R; Gneiss C; Künz B; Berger T; Reindl M; Deisenhammer F
Mult Scler; 2009 Aug; 15(8):977-83. PubMed ID: 19465447
[TBL] [Abstract][Full Text] [Related]
3. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
[TBL] [Abstract][Full Text] [Related]
4. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.
Hegen H; Schleiser M; Gneiss C; Di Pauli F; Ehling R; Kuenz B; Lutterotti A; Berger T; Deisenhammer F
Mult Scler; 2012 May; 18(5):610-5. PubMed ID: 22013146
[TBL] [Abstract][Full Text] [Related]
5. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study.
Pachner AR; Warth JD; Pace A; Goelz S;
Neurology; 2009 Nov; 73(18):1493-500. PubMed ID: 19884577
[TBL] [Abstract][Full Text] [Related]
6. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
Hesse D; Sellebjerg F; Sorensen PS
Neurology; 2009 Aug; 73(5):372-7. PubMed ID: 19652141
[TBL] [Abstract][Full Text] [Related]
7. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.
Bertolotto A; Gilli F; Sala A; Capobianco M; Malucchi S; Milano E; Melis F; Marnetto F; Lindberg RL; Bottero R; Di Sapio A; Giordana MT
Neurology; 2003 Feb; 60(4):634-9. PubMed ID: 12601105
[TBL] [Abstract][Full Text] [Related]
8. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
Perini P; Calabrese M; Biasi G; Gallo P
J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
[TBL] [Abstract][Full Text] [Related]
9. Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.
Hartung HP; Freedman MS; Polman CH; Edan G; Kappos L; Miller DH; Montalbán X; Barkhof F; Petkau J; White R; Sahajpal V; Knappertz V; Beckmann K; Lanius V; Sandbrink R; Pohl C;
Neurology; 2011 Aug; 77(9):835-43. PubMed ID: 21849647
[TBL] [Abstract][Full Text] [Related]
10. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
Hegen H; Millonig A; Bertolotto A; Comabella M; Giovanonni G; Guger M; Hoelzl M; Khalil M; Killestein J; Lindberg R; Malucchi S; Mehling M; Montalban X; Polman CH; Rudzki D; Schautzer F; Sellebjerg F; Sørensen PS; Deisenhammer F
Mult Scler; 2014 Apr; 20(5):577-87. PubMed ID: 24009164
[TBL] [Abstract][Full Text] [Related]
11. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies.
Deisenhammer F; Reindl M; Harvey J; Gasse T; Dilitz E; Berger T
Neurology; 1999 Apr; 52(6):1239-43. PubMed ID: 10214750
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.
Vallittu AM; Halminen M; Peltoniemi J; Ilonen J; Julkunen I; Salmi A; Erälinna JP;
Neurology; 2002 Jun; 58(12):1786-90. PubMed ID: 12084878
[TBL] [Abstract][Full Text] [Related]
14. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort.
McKay F; Schibeci S; Heard R; Stewart G; Booth D
J Immunol Methods; 2006 Mar; 310(1-2):20-9. PubMed ID: 16448664
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial.
Goodin DS; Hartung HP; O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Jeffery D; Kappos L; Bogumil T; Knappertz V; Sandbrink R; Beckmann K; White R; Petkau J; Pohl C;
Mult Scler; 2012 Feb; 18(2):181-95. PubMed ID: 21952094
[TBL] [Abstract][Full Text] [Related]
16. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
[TBL] [Abstract][Full Text] [Related]
17. Anti-interferon beta antibody titers strongly correlate between two bioassays and in vivo biomarker expression, and indicates that a titer of 150 TRU/mL is a biologically functional cut-point.
Hermanrud C; Ryner ML; Engdahl E; Fogdell-Hahn A
J Interferon Cytokine Res; 2014 Jul; 34(7):498-504. PubMed ID: 24444338
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.
Jungedal R; Lundkvist M; Engdahl E; Ramanujam R; Westerlind H; Sominanda A; Hillert J; Fogdell-Hahn A
Mult Scler; 2012 Dec; 18(12):1775-81. PubMed ID: 22551640
[TBL] [Abstract][Full Text] [Related]
19. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity.
Sominanda A; Rot U; Suoniemi M; Deisenhammer F; Hillert J; Fogdell-Hahn A
Mult Scler; 2007 Mar; 13(2):208-14. PubMed ID: 17439886
[TBL] [Abstract][Full Text] [Related]
20. Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis.
Pozzilli C; Antonini G; Bagnato F; Mainero C; Tomassini V; Onesti E; Fantozzi R; Galgani S; Pasqualetti P; Millefiorini E; Spadaro M; Dahlke F; Gasperini C
J Neurol; 2002 Jan; 249(1):50-6. PubMed ID: 11954868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
